دورية أكاديمية
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
| العنوان: | Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. |
|---|---|
| المؤلفون: | Grosser R; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Cherkassky L; Surgical Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer, New York, NY 10065, USA., Chintala N; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Adusumilli PS; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: adusumip@mskcc.org. |
| المصدر: | Cancer cell [Cancer Cell] 2019 Nov 11; Vol. 36 (5), pp. 471-482. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Cambridge, Mass. : Cell Press, c2002- |
| مواضيع طبية MeSH: | Antineoplastic Agents, Immunological/*therapeutic use , Costimulatory and Inhibitory T-Cell Receptors/*antagonists & inhibitors , Immunotherapy, Adoptive/*methods , Neoplasms/*therapy , Receptors, Chimeric Antigen/*immunology, Animals ; Antineoplastic Agents, Immunological/pharmacology ; Combined Modality Therapy/methods ; Costimulatory and Inhibitory T-Cell Receptors/immunology ; Costimulatory and Inhibitory T-Cell Receptors/metabolism ; Disease Models, Animal ; Humans ; Neoplasms/immunology ; Neoplasms/pathology ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Tumor Escape/drug effects ; Tumor Escape/immunology ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology |
| مستخلص: | Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an exhausted immune response. However, response rates remain limited, likely secondary to a lack of a tumor-reactive immune infiltrate. Chimeric antigen receptor (CAR) T cells may provide the necessary tumor-targeting immune infiltrate and a highly specific antitumor immune response. This can be further amplified by the addition of CPB agents, which serve to counteract the immune inhibitory environment undermining optimal CAR T cell efficacy. Herein, we review preclinical and clinical combination therapy with CAR T cells and CPB agents, with a focus on solid tumor malignancies. (Copyright © 2019 Elsevier Inc. All rights reserved.) |
| References: | Cancer Res. 2016 Mar 15;76(6):1578-90. (PMID: 26979791) Oncoimmunology. 2016 Sep 20;5(11):e1235107. (PMID: 27999753) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290) Clin Cancer Res. 2012 Apr 15;18(8):2199-209. (PMID: 22407828) Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7. (PMID: 19088198) Nat Rev Cancer. 2003 Jan;3(1):35-45. (PMID: 12509765) Mol Ther. 2016 Jun;24(6):1135-1149. (PMID: 27019998) Nat Med. 2015 Jun;21(6):581-90. (PMID: 25939063) Mol Ther. 2018 Nov 7;26(11):2542-2552. (PMID: 30415658) Cancer Immunol Res. 2018 Feb;6(2):189-200. (PMID: 29339377) Science. 2011 Mar 25;331(6024):1565-70. (PMID: 21436444) Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236) Immunol Rev. 2017 Mar;276(1):52-65. (PMID: 28258699) Nature. 2016 Jan 28;529(7587):490-5. (PMID: 26735016) Sci Transl Med. 2014 Feb 19;6(224):224ra25. (PMID: 24553386) Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070) Immunity. 1995 Nov;3(5):541-7. (PMID: 7584144) Immunity. 2016 May 17;44(5):955-72. (PMID: 27192563) Oncotarget. 2016 Jun 7;7(23):34341-55. (PMID: 27145284) Blood. 2017 Jun 22;129(25):3322-3331. (PMID: 28408462) Nat Immunol. 2002 Nov;3(11):991-8. (PMID: 12407406) Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648) Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531) N Engl J Med. 2003 Jan 16;348(3):203-13. (PMID: 12529460) Cancer Discov. 2018 Oct;8(10):1219-1226. (PMID: 30135176) Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. (PMID: 27837027) Clin Cancer Res. 2013 Jan 15;19(2):462-8. (PMID: 23169436) N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870) Lancet. 2015 Feb 7;385(9967):517-528. (PMID: 25319501) N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992) Nat Biotechnol. 2015 Feb;33(2):187-197. (PMID: 25513782) J Clin Oncol. 2005 Dec 10;23(35):8968-77. (PMID: 16204013) Sci Transl Med. 2015 Feb 18;7(275):275ra22. (PMID: 25696001) Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. (PMID: 12218188) Cancer Discov. 2014 May;4(5):522-6. (PMID: 24795012) Sci Transl Med. 2012 Mar 28;4(127):127ra37. (PMID: 22461641) Cancer Immunol Res. 2014 Feb;2(2):154-66. (PMID: 24778279) Mol Cancer Ther. 2009 Oct;8(10):2872-81. (PMID: 19825805) Nat Biotechnol. 2018 Oct;36(9):847-856. (PMID: 30102295) J Exp Med. 2015 Jun 29;212(7):1125-37. (PMID: 26034050) Blood. 2011 Nov 3;118(18):4817-28. (PMID: 21849486) Cancer J. 2010 Jul-Aug;16(4):399-403. (PMID: 20693853) N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127) N Engl J Med. 2015 Jan 22;372(4):320-30. (PMID: 25399552) Nature. 2017 Nov 23;551(7681):512-516. (PMID: 29132146) Front Immunol. 2018 May 03;9:978. (PMID: 29774034) Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7. (PMID: 12682289) Mol Ther. 2010 Apr;18(4):843-51. (PMID: 20179677) Cancer Immunol Immunother. 2015 Jul;64(7):817-29. (PMID: 25850344) Oncoimmunology. 2015 Jan 23;4(3):e994446. (PMID: 25949921) Sci Transl Med. 2014 Nov 5;6(261):261ra151. (PMID: 25378643) J Clin Invest. 2018 Feb 1;128(2):580-588. (PMID: 29337303) Cancer Discov. 2016 Feb;6(2):133-46. (PMID: 26503962) Cytotherapy. 2016 Nov;18(11):1393-1409. (PMID: 27592405) Nat Med. 2015 May;21(5):524-9. (PMID: 25849134) Clin Cancer Res. 2011 Jul 15;17(14):4719-30. (PMID: 21610146) Nat Med. 2003 May;9(5):562-7. (PMID: 12704383) Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505) Science. 2018 Mar 23;359(6382):1361-1365. (PMID: 29567707) Nature. 2014 Nov 27;515(7528):563-7. (PMID: 25428504) N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174) Science. 2016 Apr 8;352(6282):227-31. (PMID: 26966191) Blood. 2017 Feb 23;129(8):1039-1041. (PMID: 28031179) J Transl Med. 2013 Aug 12;11:187. (PMID: 23937772) N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456) Cell. 2016 Feb 11;164(4):770-9. (PMID: 26830879) Oncoimmunology. 2018 Jan 9;7(3):e1395997. (PMID: 29399394) J Clin Invest. 2016 Aug 1;126(8):3130-44. (PMID: 27454297) Cancer Res. 2017 Apr 15;77(8):2040-2051. (PMID: 28235763) Nat Biotechnol. 2013 Jan;31(1):71-5. (PMID: 23242161) Science. 2016 Mar 25;351(6280):1463-9. (PMID: 26940869) J Clin Oncol. 2017 Jul 1;35(19):2125-2132. (PMID: 28441111) Clin Cancer Res. 2013 Oct 15;19(20):5636-46. (PMID: 23873688) Nature. 2018 Jan 18;553(7688):347-350. (PMID: 29320474) J Immunol. 2007 May 1;178(9):5552-62. (PMID: 17442937) JAMA. 2016 Apr 19;315(15):1600-9. (PMID: 27092830) Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. (PMID: 28912137) N Engl J Med. 2016 Jun 30;374(26):2542-52. (PMID: 27093365) N Engl J Med. 2017 Dec 28;377(26):2545-2554. (PMID: 29226764) Cancer Cell. 2015 Nov 9;28(5):638-652. (PMID: 26525103) Blood. 2012 Mar 22;119(12):2709-20. (PMID: 22160384) Sci Rep. 2017 Apr 7;7(1):737. (PMID: 28389661) Cancer Cell. 2018 Apr 9;33(4):581-598. (PMID: 29634946) Sci Transl Med. 2013 Dec 11;5(215):215ra172. (PMID: 24337479) Science. 2015 Apr 3;348(6230):74-80. (PMID: 25838376) Cancer Res. 2003 Oct 1;63(19):6501-5. (PMID: 14559843) Clin Cancer Res. 2015 Sep 1;21(17):3969-76. (PMID: 25944800) Nature. 2017 May 4;545(7652):60-65. (PMID: 28397821) N Engl J Med. 2013 Jul 11;369(2):122-33. (PMID: 23724867) Science. 2016 Jan 1;351(6268):84-8. (PMID: 26628643) N Engl J Med. 2011 Jun 30;364(26):2517-26. (PMID: 21639810) J Clin Invest. 2011 May;121(5):1822-6. (PMID: 21540550) Nat Commun. 2016 Feb 17;7:10501. (PMID: 26883990) Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870) Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592) J Clin Oncol. 2012 Jul 20;30(21):2678-83. (PMID: 22711850) Nat Med. 2007 Jan;13(1):84-8. (PMID: 17159987) J Clin Oncol. 2013 Feb 1;31(4):490-8. (PMID: 23269987) Nature. 2014 Nov 27;515(7528):558-62. (PMID: 25428503) Mol Ther. 2017 Sep 6;25(9):2214-2224. (PMID: 28602436) Cancer Immunol Immunother. 2019 Mar;68(3):365-377. (PMID: 30523370) Clin Cancer Res. 2017 May 1;23(9):2255-2266. (PMID: 27815355) Mol Ther Nucleic Acids. 2017 Dec 15;9:312-321. (PMID: 29246309) Science. 2016 May 6;352(6286):658-60. (PMID: 27151852) Science. 2018 Mar 23;359(6382):1350-1355. (PMID: 29567705) J Clin Oncol. 2006 May 1;24(13):e20-2. (PMID: 16648493) Blood. 2010 Nov 18;116(20):4099-102. (PMID: 20668228) Clin Cancer Res. 2014 Aug 15;20(16):4262-73. (PMID: 24919573) Cancer Discov. 2013 Apr;3(4):388-98. (PMID: 23550147) Clin Cancer Res. 2014 Feb 15;20(4):972-84. (PMID: 24352643) Nature. 2016 May 23;534(7607):402-6. (PMID: 27281199) N Engl J Med. 2018 Feb 1;378(5):449-459. (PMID: 29385376) J Clin Oncol. 2017 May 10;35(14):1542-1549. (PMID: 28328302) Sci Transl Med. 2016 Mar 2;8(328):328rv4. (PMID: 26936508) Sci Transl Med. 2013 Aug 28;5(200):200ra116. (PMID: 23986400) J Clin Immunol. 2012 Oct;32(5):1059-70. (PMID: 22526592) Nat Med. 2016 Dec;22(12):1402-1410. (PMID: 27775706) Science. 1996 Mar 22;271(5256):1734-6. (PMID: 8596936) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS; R01 CA235667 United States CA NCI NIH HHS; R01 CA236615 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: CAR T cell; PD-1; checkpoint blockade; chimeric antigen receptor; immunotherapy |
| المشرفين على المادة: | 0 (Antineoplastic Agents, Immunological) 0 (Costimulatory and Inhibitory T-Cell Receptors) 0 (Receptors, Chimeric Antigen) |
| تواريخ الأحداث: | Date Created: 20191113 Date Completed: 20200527 Latest Revision: 20231113 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC7171534 |
| DOI: | 10.1016/j.ccell.2019.09.006 |
| PMID: | 31715131 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1878-3686 |
|---|---|
| DOI: | 10.1016/j.ccell.2019.09.006 |